Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Itraconazole and GST-HG171/Ritonavir in Healthy Chinese Adults
NCT06087055Phase 1Completed
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atilotrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoint: Maximum Observed Concentration of GST-HG171 at Day 14. Started May 2023; status: completed.
02
Drugs
atilotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06087055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087055.